

## **Radiopharm to present at NWR Virtual Healthcare Conference**

Sydney, Australia – 19 March 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

Chief Operating Officer Vittorio Puppo will present at 9:00am AEDT on Thursday 21 March 2024.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: [https://us02web.zoom.us/webinar/register/WN\\_z-nNb9jZQum5W6o\\_HIFn6g](https://us02web.zoom.us/webinar/register/WN_z-nNb9jZQum5W6o_HIFn6g)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company’s website and social media channels.

Questions can be submitted on the day or sent in advance to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For more information please visit: <https://nwrcommunications.com/healthconf>

### **About Radiopharm Theranostics**

Radiopharm Theranostics is a clinical stage company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on the ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumour cancers including lung, pancreas and brain. Learn more at [Radiopharmtheranostics.com](http://Radiopharmtheranostics.com).

**Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.**

### **For more information:**

Riccardo Canevari  
CEO & Managing Director  
P: +1 862 309 0293  
E: [rc@radiopharmtheranostics.com](mailto:rc@radiopharmtheranostics.com)

Matt Wright  
NWR Communications  
P: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**ASX ANNOUNCEMENT  
19 MARCH 2024**



**Follow Radiopharm Theranostics:**

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

InvestorHub – <https://investorhub.radiopharmtheranostics.com/>

